For research use only. Not for therapeutic Use.
PPNDS tetrasodium is a selective and competitive meprin β inhibitor (IC50: 80 nM, Ki: 8 nM), and also inhibits ADAM10 (IC50: 1.2 μM). PPNDS tetrasodium is also a P2X1 receptor antagonist. PPNDS is an agonist for the ATP receptor of Paramecium. PPNDS tetrasodium potently inhibits polymerases from viruses. PPNDS tetrasodium can be used in the research of infection and cancers[1][3][4].
PPNDS tetrasodium inhibits meprin β (IC50: 80 nM) and meprin α (67 μM)[1].
PPNDS tetrasodium (0-10 μM, 15 min) inhibits mNV-RdRp (murine Norovirus RNA-dependent RNA-polymerase) with an IC50 value of 0.88 μM[2].
PPNDS tetrasodium (0.025-10 µM) potently inhibits polymerases from six viruses spanning the three Caliciviridae genera tested (IC50 range: 0.1-2.3 μM)[4].
| Catalog Number | I010389 |
| CAS Number | 1021868-77-8 |
| Synonyms | tetrasodium;3-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonatooxymethyl)pyridin-2-yl]diazenyl]-7-nitronaphthalene-1,5-disulfonate |
| Molecular Formula | C18H11N4Na4O14PS2 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H15N4O14PS2.4Na/c1-8-17(24)13(6-23)14(7-36-37(27,28)29)18(19-8)21-20-9-2-11-12(15(3-9)38(30,31)32)4-10(22(25)26)5-16(11)39(33,34)35;;;;/h2-6,24H,7H2,1H3,(H2,27,28,29)(H,30,31,32)(H,33,34,35);;;;/q;4*+1/p-4 |
| InChIKey | XHWIRFKQZFSILU-UHFFFAOYSA-J |
| SMILES | CC1=C(C(=C(C(=N1)N=NC2=CC3=C(C=C(C=C3S(=O)(=O)[O-])[N+](=O)[O-])C(=C2)S(=O)(=O)[O-])COP(=O)([O-])[O-])C=O)O.[Na+].[Na+].[Na+].[Na+] |
| Reference | [1]. Franck Madoux, et al. Development of high throughput screening assays and pilot screen for inhibitors of metalloproteases meprin α and β. Biopolymers. 2014 Sep;102(5):396-406. [2]. Romina Croci, et al. PPNDS inhibits murine Norovirus RNA-dependent RNA-polymerase mimicking two RNA stacking bases. FEBS Lett. 2014 May 2;588(9):1720-5. [3]. Christopher R Wood, et al. PPNDS is an agonist, not an antagonist, for the ATP receptor of Paramecium. J Exp Biol. 2003 Feb;206(Pt 3):627-36. [4]. Natalie E Netzler, et al. Broad-spectrum non-nucleoside inhibitors for caliciviruses. Antiviral Res. 2017 Oct;146:65-75. |
